Electrochemical Treatment of Cancer. III
- 1 April 1990
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 13 (2) , 164-166
- https://doi.org/10.1097/00000421-199004000-00015
Abstract
Plasma pharmacokinetics of Adriamycin (doxorubicin) has been studied after intraneoplastic administration during electrochemical treatment to patients with lung cancer that is noncurable with radiotherapy, surgery, or chemotherapy. Intraneoplastic administration of Adriamycin via the anode resulted in a dramatic change of the pharmacokinetic pattern in plasma as compared with what has been previously observed after intravenous administration. A fivefold reduction of the area under the plasma concentration time curve and a 25-fold reduction of the maximum plasma concentration was observed.This publication has 5 references indexed in Scilit:
- Electrochemical Treatment of Cancer. IIAmerican Journal of Clinical Oncology, 1990
- Pharmacokinetic study of IV infusions of adriamycinEuropean Journal of Clinical Pharmacology, 1985
- Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous InfusionAnnals of Internal Medicine, 1982
- Reversed-phase liquid chromatographic determination of plasma levels of adriamycin and adriamycinolJournal of Chromatography B: Biomedical Sciences and Applications, 1979
- Extraction of Daunorubicin and Doxorubicin and Their Hydroxyl Metabolites: Self-Association in Aqueous SolutionJournal of Pharmaceutical Sciences, 1978